1,028 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Traynor Capital Management Inc.

Traynor Capital Management Inc. acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the third quarter, HoldingsChannel reports. The fund acquired 1,028 shares of the company’s stock, valued at approximately $201,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Prevail Innovative Wealth Advisors LLC grew its holdings in Zoetis by 24.5% in the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after buying an additional 3,738 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its holdings in Zoetis by 58.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock valued at $7,095,000 after buying an additional 15,491 shares in the last quarter. Duality Advisers LP grew its holdings in Zoetis by 43.7% in the 1st quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock valued at $6,877,000 after buying an additional 12,359 shares in the last quarter. M&G Plc acquired a new position in Zoetis in the 1st quarter valued at $19,819,000. Finally, Cetera Investment Advisers grew its holdings in Zoetis by 275.2% in the 1st quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after buying an additional 70,476 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on ZTS shares. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $221.44.

Zoetis Stock Performance

NYSE:ZTS opened at $181.27 on Wednesday. The stock’s 50-day simple moving average is $189.02 and its 200 day simple moving average is $178.25. The firm has a market capitalization of $82.12 billion, a PE ratio of 34.93, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue was up 8.3% compared to the same quarter last year. During the same period last year, the firm posted $1.41 earnings per share. On average, analysts anticipate that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 33.14%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.